ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tirabrutinib

Also written as “Tirabrutinib” and “ONO-4059”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Pemphigus · Chronic Urticaria · Lymphoma, Non-Hodgkin · Sjogren's Syndrome, led by 2 companies.

Drug pageTirabrutinib: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 16, 201613 company-led studies, 4 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences80 open or runningphase 2since Nov 16, 2016Jul 6, 2012none ahead
Ono Pharmaceuticalits history only54 open or runningphase 3since Nov 7, 2024Jun 16, 2021Sep 30, 2027phase 3 · NCT06696716

Also a collaborator on its studies: Lakefront Biotherapeutics NV.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2012First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT01659255 · 90 enrolled · France, United Kingdom
  2. May 27, 20152 phase 1 studiesNCT02457598, NCT02457559
  3. Dec 3, 2015Phase 1 study in Arthritis, RheumatoidNCT02626026 · 42 enrolled · United States
  4. Jun 9, 2016Named tirabrutinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ONO-4059
  5. Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02968563 · 35 enrolled · Germany
  6. Dec 2, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02983617 · 36 enrolled · Germany
  7. Mar 31, 2017Phase 2 study in Sjogren's SyndromeNCT03100942 · 152 enrolled · United States, Poland, Spain and more
  8. Mar 30, 2021Phase 2 study in Chronic UrticariaNCT04827589

TargetBeta

BTK →read by rule
“An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 8 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04827589Chronic Urticaria2WithdrawnApr 20220
NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more2CompletedJan 10, 2019152
NCT02983617Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedFeb 20, 201936
NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedJun 17, 201935
NCT02626026Arthritis, Rheumatoid · United States1CompletedSep 1, 201642
NCT02457598B-cell Malignancies · United States, France, United Kingdom1TerminatedSep 25, 2024203
NCT02457559Recurrence · France, United Kingdom1CompletedDec 30, 202029
NCT01659255Lymphoma, Non-Hodgkin · France, United Kingdom1CompletedFeb 23, 201590

How it is read

Names in the registry

  • “Tirabrutinib”, 13 entries
  • “ONO-4059”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.